Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMD with Carboplatin/Paclitaxel in Ovarian Cancer
NCT05921149Not yet recruiting
- Sponsor
- Endeavor Health
- Start
- May 2024
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Randomised, open-label trial (2 arms), sponsored by Endeavor Health. Primary endpoints: Gastrointestinal Toxicity at 6 months, Neurotoxicity at 6 months and 4 more. Planned start May 2024; status: not yet recruiting.
Beyond the preview
Go deeper on NCT05921149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05921149.